Atjaunināt sīkdatņu piekrišanu

Handbook of Drug-Eluting Stents [Hardback]

(Erasmus University Medical Center, Rotterdam, The Netherlands), (Glenfield General Hospital, Leicester, UK)
  • Formāts: Hardback, 392 pages, height x width: 246x189 mm, weight: 1224 g, 50 Line drawings, black and white; 100 Illustrations, color; 75 Illustrations, black and white
  • Izdošanas datums: 14-Jun-2005
  • Izdevniecība: CRC Press
  • ISBN-10: 1841841323
  • ISBN-13: 9781841841328
Citas grāmatas par šo tēmu:
  • Hardback
  • Cena: 217,27 €
  • Grāmatu piegādes laiks ir 3-4 nedēļas, ja grāmata ir uz vietas izdevniecības noliktavā. Ja izdevējam nepieciešams publicēt jaunu tirāžu, grāmatas piegāde var aizkavēties.
  • Daudzums:
  • Ielikt grozā
  • Piegādes laiks - 4-6 nedēļas
  • Pievienot vēlmju sarakstam
  • Formāts: Hardback, 392 pages, height x width: 246x189 mm, weight: 1224 g, 50 Line drawings, black and white; 100 Illustrations, color; 75 Illustrations, black and white
  • Izdošanas datums: 14-Jun-2005
  • Izdevniecība: CRC Press
  • ISBN-10: 1841841323
  • ISBN-13: 9781841841328
Citas grāmatas par šo tēmu:
Over the past few years, the focus in interventional cardiology research has centered on reducing restenosis with the use of antiproliferative pharmacological agents. The use of these drugs, hitherto, has failed, most probably because of low active drug levels at the target site. This problem led to the development of local drug delivery using stents, since they can serve as a reservoir for local drug administration and are in immediate contract with the coronary artery wall, thus ensuring maximum delivery of the pharmacological agent. Drug-eluting stents provide an entirely new spectrum of potential therapies for restenosis.

Handbook of Drug-Eluting Stents, under the editorial direction of Patrick Serruys, one of the world's leading interventional cardiologists, and Tony Gershlick, a pioneer in the field of drug-eluting stents, provides the reader with up-to-date information on which stents and pharmacological agents in use or about to be launched, the kinetics of the drugs involved, and what the future may hold.

Short Contents
List of contributors
xi
Preface xix
PART I BACKGROUND AND INTRODUCTION
1(84)
Restenosis following percutaneous coronary interventions: a clinical problem
3(12)
Eugenia Nikolsky
Roxana Mehran
Dale T Ashby
George D Dangas
Alexandra J Lansky
Gregg W Stone
Jeffrey W Moses
Martin B Leon
Histopathology of restenosis
15(10)
Andrew J Carter
Philip Tsao
Cellular mechanisms of restenosis: conventional dogma and novel theory
25(14)
Robert S Schwartz
Molecular basis of restenosis and potential therapeutic targets
39(8)
Yiming Yang
Andrew R Marks
Steven O Marx
Principles of continuum pharmacokinetics in stent-based drug elution
47(10)
Chao-Wei Hwang
Elazer R Edelman
Importance of the toxic/therapeutic window
57(8)
Arun Kuchela
Campbell Rogers
Drug delivery coatings
65(10)
Michael Kuehler
Ivan De Scheerder
The importance of the drug platform: coated, uncoated, sleeves, and new concepts
75(10)
Dougal R McClean
Frank Litvack
PART II DRUG-STENT PROGRAMS
85(280)
Rapamycin structure and mechanism of action
87(6)
Steven O Marx
Andrew R Marks
Sirolimus-coated stent: preclinical studies
93(10)
Andrew J Carter
Gregory A Kopia
Robert Falotico
Nonrandomized registries for de novo lesions (FIM) and in-stent restenosis
103(6)
J Eduardo Sousa
Alexandre C Abizaid
Marco A Costa
Amanda GMR Sousa
Fausto Feres
Ibraim Pinto
The RAVEL trial
109(12)
Marie-Claude Morice
The SIRIUS, E-SIRIUS, and C-SIRIUS trials
121(12)
Michael Schluter
Joachim Schofer
Sirolimus-eluting coronary stent in high-risk patients with complex lesions: subset data from controlled clinical trials and registries
133(12)
Pedro A Lemos
Local vascular delivery of paclitaxel: background, mechanisms, and pharmacodynamic properties
145(8)
Mary E Russell
Edmund A Bermudez
Simona Cipra
Preclinical experience with the paclitaxel-eluting stent: the Boston Scientific Program
153(4)
Douglas E Drachman
Campbell Rogers
The Quanam drug-eluting stent and the SCORE trial
157(8)
Eberhard Grube
Initial experiences with paclitaxel-eluting stents for treatment of de novo as well as in-stent restenotic lesions: TAXUS I and TAXUS III
165(8)
Eberhard Grube
Patrick W Serruys
The Boston Scientific Taxus trials
173(12)
Antonio Colombo
Gregg W Stone
Local delivery of paclitaxel as a stent coating: biology and clinical implications
185(6)
Alan W Heldman
Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT)
191(10)
Seung-Jung Park
Patency Pilot study: a negative trial, in context
201(4)
Alan W Heldman
Paclitaxel-eluting stents---the ELUTES trial
205(4)
Neil Swanson
Anthony H Gershlick
Vascular Endothelial Growth Factor (VEGF)-eluting stents
209(6)
Neil Swanson
Anthony H Gershlick
The Millennium Matrix™ Coronary Stent
215(12)
Rajesh Vaishnav
Devesh Kothwala
Rohit Chand
The Conor drug delivery stent
227(6)
Joseph Aragon
Frank Litvack
Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study (the ACTION trial)
233(10)
Patrick W Serruys
John A Ormiston
Muzaffer Degertekin
Kengo Tanabe
J Eduardo Sousa
Eberhard Grube
Peter den Heijer
Pim de Feyter
Pawel Buszman
Albert Schomig
Jean Marco
Lech Polonski
Leif Thuesen
Andreas M Zeiher
JH Nicholas Bett
Maarten J Suttorp
Helmut D Glogar
Mark Pitney
Gerard T Wilkins
Robert Whitbourn
Susan Veldhof
Karine Miquel
Rachel Johnson
Renu Virmani
Guidant deliver II study: prospective, nonrandomized, multicenter evaluation of the ACHIEVE™ paclitaxel-eluting coronary stent system in the treatment of lesions with high risk of revascularization due to restenosis
243(2)
Eberhard Grube
Guidant deliver clinical trial: prospective, randomized, single-blinded, parallel-group (two-arm), multicenter, clinical evaluation of the RX ACHIEVE™ drug-eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions
245(2)
William O'Neill
William D Knopf
Batimastat: mode of action, preclinical, and clinical studies
247(14)
Ivan De Scheerder
Xiaoshun Liu
Bernard Chevalier
Guy LeClerc
Anthony Collias
The prevention and treatment of in-stent restenosis---the current challenge for coronary intervention
261(12)
Sandra E Burke
Tony M Chou
Dexamethasone: mode of action, preclinical, and clinical studies
273(12)
Ivan De Scheerder
Xiaoshun Liu
Yanming Huang
Eric Verbeken
Joseph Dens
Walter Desmet
Jan Piessens
17β-estradiol-eluting stents---a potential therapy in the prevention of restenosis
285(10)
Gishel New
Nicholas Kipshidze
Alexandre C Abizaid
Antonio Colombo
An advanced antisense (AVI-4126) for local and stent-based delivery for prevention of restenosis after PCI (current status and future developments)
295(10)
Nicholas Kipshidze
Jeffrey W Moses
Patrick Iversen
Patrick W Serruys
Martin B Leon
The Endeavor Drug-Eluting Stent program
305(8)
Ian T Meredith
Terumo statin releasing stent (preclinical results)
313(10)
Kengo Tanabe
Haruo Ishiyama
Willem J van der Giessen
Patrick W Serruys
Duraflex™ Drug-Eluting Coronary Stent System
323(6)
Alexandre C Abizaid
Vinayak D Bhat
Andrew J Carter
Guy LeClerc
Lynn Morrison
John Yan
Genous™ Bio-engineered R stent™: development and the HEALING clinical evaluations
329(12)
Stephen Rowland
Robert Cottone
H Richard Davis
Margaret Yoklavich
Michael JB Kutryk
Everolimus-eluting stents
341(8)
Eberhard Grube
Lutz Buellesfeld
Contemporary state of drug-eluting stents
349(16)
Andrew TL Ong
Pedro A Lemos
Anthony H Gershlick
Patrick W Serruys
Index 365


Patrick W. Serruys